Organization | University of Essex

University of Essex Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2012

NCT01666587

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Mid and South Essex NHS Foundation Trust

Active Ingredients

Drugs in Phase 4 Trials (1)

human fibrin (Tisseel) (1 trial)

Drugs in Phase 3 Trials (2)

anakinra (Kineret) (1 trial)

methylprednisolone (medrol) (1 trial)

Drugs in Other Trials (7)

alpha-lipoic acid (1 trial)

beta carotene (solatene) (1 trial)

copper (cu-7) (1 trial)

ibuprofen (motrin) (1 trial)

prolycopene (1 trial)

selenium (1 trial)

zinc dichloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Gout (Phase 3)

Kidney Diseases (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 10